@article{e575f86cf6a4422fbfbe54dbf9426f2d,
title = "Japanese optic-spinal MS: Is it MS or neuromyelitis optica and does the answer dictate treatment?",
author = "Weinshenker, {Brian G.} and Wingerchuk, {Dean M.}",
note = "Funding Information: Dr. Weinshenker serves on data safety monitoring boards for Novartis and Biogen Idec; serves on the editorial boards of the Canadian Journal of Neurological Sciences and the Turkish Journal of Neurology ; has received research support from Genzyme Corporation and the Guthy-Jackson Charitable Foundation; and receives license royalties from RSR Ltd. for a patent re: Aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica. Dr. Wingerchuk serves as a consultant for Novartis and receives research support from Alexion Pharmaceuticals, Inc., Genentech, Inc., Genzyme Corporation, the National Multiple Sclerosis Society, and the Guthy-Jackson Charitable Foundation.",
year = "2010",
month = oct,
day = "19",
doi = "10.1212/WNL.0b013e3181f88382",
language = "English (US)",
volume = "75",
pages = "1404--1405",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "16",
}